Optimizing the Use of Biologics for Moderate to Sever Plaque Psoriasis

This CME-certified activity provides a comprehensive update on the diagnosis and treatment of patients with moderate to severe plaque psoriasis.

Medium: i-Newsletter

Commercial Support Statetements: This activity is supported by independent education grants from AbbVie, Inc., and Novartis Pharmaceuticals Corporation.

Joint Provider: MCM Education

Target Audience

This activity is intended for dermatologists and other clinicians involved in the treatment of patients with moderate to severe plaque psoriasis.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  •     Describe characteristics of patients with moderate to severe plaque psoriasis who may benefit from treatment with systemic therapies.
  •     Summarize safety and efficacy data of biologic therapies currently approved for the treatment of moderate to severe plaque psoriasis.
  •     Compare the mechanisms of action of emerging investigational biologic agents for moderate to severe plaque psoriasis that selectively target specific components of the immune system.
  •     Discuss best practices for the use of biologic therapies, including combination therapy, with current systemic phototherapeutic and topical agents as well as managing treatment failures.
Additional information
ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation
Activity opens: 
10/29/2014
Activity expires: 
10/29/2015

Alan Menter, MD 
Chief, Division of Dermatology 
Baylor University Medical Center 
Clinical Professor of Dermatology 
University of Texas, Southwestern Medical School 
Dallas, TX 

Craig Leonardi, MD 
Clinical Professor, Dermatology 
St. Louis University 
Central Dermatology 
St. Louis, MO 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses and other health care professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board. 

Accreditation Period

Activity opens: 
10/29/2014
Activity expires: 
10/29/2015
Please login or create an account to proceed.